Heart & Cardiovascular Disease • ICD-10-CM I48.4
Atypical atrial flutter
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM I48.4 • 3 Linked .gov / PubMed Citations
•
Governance: Dr. Marcus Thorne, MD, FACC (NPI #1184629314)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Atypical atrial flutter Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Atypical atrial flutter (ICD-10-CM I48.4), Heart & Cardiovascular Disease protocols prioritize transthoracic echocardiography [Atypical atrial flutter I48.4] paired with baseline and interval Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] assessment.
- 2 Real-world patient consensus: Mapped to Heart & Cardiovascular Disease under ICD-10-CM I48.4 for Atypical atrial flutter clinical workups.
- 3 Typical cash cost range: Primary evaluation for Atypical atrial flutter incorporates transthoracic echocardiography [Atypical atrial flutter I48.4] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Atypical atrial flutter: maintaining Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] within < 70 mg/dL (I48.4).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Atypical atrial flutter
What Is Atypical atrial flutter?
For patients presenting with Atypical atrial flutter (ICD-10-CM I48.4), Heart & Cardiovascular Disease protocols prioritize transthoracic echocardiography [Atypical atrial flutter I48.4] paired with baseline and interval Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Atypical atrial flutter (code I48.4) is myocardial oxygen supply-demand in Atypical atrial flutter (I48.4: mismatch), which Heart & Cardiovascular Disease clinicians address while surveilling Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] (< 70 mg/dL (I48.4)).
Common Symptoms & Clinical Signs
- • Presentation of Atypical atrial flutter (I48.4): unexplained lower-extremity ankle in Atypical atrial flutter (I48.4: edema or rapid)
- • Secondary Atypical atrial flutter clinical sign: reduced exercise tolerance in Atypical atrial flutter (I48.4: and premature cardiovascular)
- • Symptom flares in Atypical atrial flutter correlating with Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] deviation outside < 70 mg/dL (I48.4)
- • Functional heart & vascular impact requiring transthoracic echocardiography [Atypical atrial flutter I48.4] evaluation (I48.4)
Atypical atrial flutter Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I48.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Atypical atrial flutter I48.4] | < 70 mg/dL (I48.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Atypical atrial flutter (I48.4: Fraction (LVEF)) | 55% – 70% (I48.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Atypical atrial flutter I48.4] | < 100 pg/mL (I48.4) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Atypical atrial flutter
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Quetiapine Fumarate Seroquel • RxCUI 312743 | Atypical Antipsychotic | 92% | $0.0209 | $ 5.35 /mo |
| Clozaril (Clozapine) Clozaril • RxCUI 104775 | Atypical Antipsychotic | 94% | $6.2959 | $ 461.80 /mo |
| Cariprazine Vraylar • RxCUI RXN-61874130-2392 | Atypical Antipsychotic | 88% | $48.5295 | $ 185.00 /mo |
| Asenapine Secuado, Saphris • RxCUI 859975 | Atypical Antipsychotic | 94% | $2.3627 | $ 57.01 /mo |
| Risperidone Risperdal Consta, Risperdal • RxCUI 312830 | Atypical Antipsychotic | 87% | $0.0358 | $ 5.36 /mo |
| Vraylar (Cariprazine) Vraylar • RxCUI RXN-B61874130 | Atypical Antipsychotic | 94% | $48.5295 | $ 640.00 /mo |
| Lybalvi (Olanzapine and Samidorphan L-Malate) Lybalvi • RxCUI 2570398 | Atypical Antipsychotic | 81% | $52.5028 | $ 640.00 /mo |
| Latuda (Lurasidone Hydrochloride) Latuda • RxCUI 1040036 | Atypical Antipsychotic | 80% | $45.3287 | $ 7.45 /mo |
| Olanzapine and Fluoxetine (Olanzapine and Fuoxetine) Olanzapine and Fluoxetine • RxCUI 403970 | Atypical Antipsychotic | 85% | $4.0280 | $ 298.52 /mo |
| Saphris (Asenapine Maleate) Saphris • RxCUI 1606337-B04562410 | Atypical Antipsychotic | 93% | $20.1874 | $ 57.01 /mo |
| Seroquel XR (Quetiapine) Seroquel XR • RxCUI 721791 | Atypical Antipsychotic | 93% | $14.1432 | $ 7.14 /mo |
| Risperdal (Risperidone) Risperdal • RxCUI 312828-B50458330 | Atypical Antipsychotic | 82% | $9.1619 | $ 5.36 /mo |
| Ziprasidone Hydrochloride (Ziprasidone HCl) Ziprasidone Hydrochloride • RxCUI 313776 | Atypical Antipsychotic | 75% | $0.2181 | $ 24.20 /mo |
| Rexulti (Brexpiprazole) Rexulti • RxCUI RXN-B59148036 | Atypical Antipsychotic | 89% | $48.3704 | $ 640.00 /mo |
| Paliperidone Invega • RxCUI 672567 | Atypical Antipsychotic | 93% | $1.0186 | $ 49.75 /mo |
| Secuado (Asenapine) Secuado • RxCUI 859975-B689680174 | Atypical Antipsychotic | 94% | $48.8310 | $ 640.00 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Atypical atrial flutter)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Lymphocyte proliferation among major depressive and dysthymic patients with As the immune variations were more pronounced in dysthymia than in major depression, chronicity of illness may be a pertinent factor in promoting immune disturbances. Journal of affective disorders • 2000-04-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 10760553 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Atypical atrial flutter Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Atypical atrial flutter community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Atypical atrial flutter.